Event Date/Time: Apr 27, 2010
The optimal management of hematologic malignancies is rapidly evolving, with newly defined standards of care and the continuing emergence of more effective therapeutic regimens and novel agents. Many of these next-generation agents and treatment approaches are associated with improved efficacy outcomes and/or reduced toxicities compared with earlier regimens. It is therefore critical that physicians stay up-to-date with these therapeutic advances to provide their patients with the best possible care. Now in its 7th year, the 2010 Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia symposium is designed to address gaps in knowledge for practicing medical oncologists and hematologists and will present current standards, practical issues, and controversies in the management of myeloma, lymphoma, and leukemia, and other hematologic malignancies. In addition, controversies in the management of these diseases will be discussed in the form of didactic lectures with panel discussions and case-based discussions with interactive response system capabilities. Emphasis will be placed on discussion of current issues in the treatment of hematologic malignancies in a practical context, focusing on conveying key findings from recent clinical studies that will most directly impact physician practice. Case discussions and patient management will be highlighted, providing a forum to discuss and debate the practical applicability of evolving clinical trial findings.
This educational program is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.
At the conclusion of this symposium, you should be able to:
Implement appropriate risk stratification measures and monitoring plans for patients with newly diagnosed myeloma, lymphoma, and leukemia
Discuss current treatment options for patients with newly diagnosed or relapsed/refractory myeloma, lymphoma, and leukemia
Assess the clinical utility of emerging novel agents for the treatment of patients with myeloma, lymphoma, and leukemia
Evaluate the role of hematopoietic stem cell transplantation for eligible patients with hematologic malignancies